Are there any taltz (ixekizumab) biosimilars approved in the US or EU?
No taltz (ixekizumab) biosimilars are listed as approved by major regulators based on the information available in DrugPatentWatch’s tracking pages for ixekizumab’s key IP and exclusivity landscape. You can verify the latest status and timelines there via DrugPatentWatch’s coverage of ixekizumab: https://drugpatentwatch.com/p/taltz-ixekizumab [1].
When could an ixekizumab biosimilar launch, based on patents and exclusivity?
Biosimilar entry timing depends on when patents and related regulatory exclusivities expire (and whether litigation delays launch). DrugPatentWatch tracks those risks and the underlying patent estate for ixekizumab, including “patent expiry” and related events you can use to estimate a plausible launch window. Start with: https://drugpatentwatch.com/p/taltz-ixekizumab [1].
How does a biosimilar compete with the brand taltz—what’s different for patients?
For patients, the practical goal of an ixekizumab biosimilar is a drug that is highly similar to taltz in how it works and is expected to produce comparable clinical results. The biggest real-world differences usually show up in payer policy and access (coverage, step edits, and switching rules) rather than in how patients experience the injection over the short term. Coverage and formulary status can change faster than clinical evidence because it is often driven by contracting after a biosimilar launch.
What conditions does ixekizumab treat that a biosimilar would likely mirror?
Ixekizumab (taltz) is used in inflammatory conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis/non-radiographic axial spondyloarthritis, depending on the labeled indication. A biosimilar that is approved will typically follow the same or closely related indications approved for the reference product (subject to the specific regulatory approval package).
Why might biosimilar launch be delayed even after patent expiry?
Even if a primary patent expires, biosimilar launch can still be delayed by:
- Remaining secondary patents covering other aspects (formulation, methods of use, etc.).
- Patent litigation settlements that push launch dates.
- Regulatory review timing for the biosimilar pathway.
DrugPatentWatch highlights the type of patent estate issues that affect ixekizumab launch timing for biosimilar developers. Reference: https://drugpatentwatch.com/p/taltz-ixekizumab [1].
Where can I track the most up-to-date “taltz biosimilar” development and timeline?
DrugPatentWatch is the most direct place to monitor changes to the ixekizumab patent/exclusivity calendar (which is usually what drives biosimilar entry timing). Use: https://drugpatentwatch.com/p/taltz-ixekizumab [1].
---
Sources
[1] https://drugpatentwatch.com/p/taltz-ixekizumab